AstraZeneca’s Covid-19 vaccine shows better-than-expected efficacy in U.S. trial
AstraZeneca said Monday that the Covid-19 vaccine it developed with the University of Oxford reduced both mild and serious forms of the disease, paving the way for a likely U.S. authorization of the vaccine.
Doctors, regulators, and government officials the world over are likely to breathe a sigh of relief at the results, which are better than expected and appear materially higher than those in previous studies.
